The largest database of trusted experimental protocols
> Physiology > Genetic Function > Loss of Heterozygosity

Loss of Heterozygosity

Loss of Heterozygosity (LOH) is a genetic phenomenon where an individual loses one of the two alleles (copies) of a gene, often resulting in increased susceptibility to diseases such as cancer.
This condition can be studied using PubCompare.ai, an AI-driven platform that optimizes LOH research by providing reproducible and accurate insights.
PubCompare.ai helps researchers effortlessly locate the best protocols from literature, pre-prints, and patents, boosting research efficiency and confidence.
With its cutting-edge technology, PubCompare.ai ensures seamless reproducibility and enhanced accuracy in LOH studies, enabling researchers to make more informed decisions and advance their field of study.
Experiecnce the power of AI-driven LOH research with PubCompare.ai.

Most cited protocols related to «Loss of Heterozygosity»

To efficiently simulate the AFS, we adopt a diffusion approach. Such approaches have a long and distinguished history in population genetics, dating back to R. A. Fischer [28] –[30] . The diffusion approach is a continuous approximation to the population genetics of a discrete number of individuals evolving in discrete generations. An important underlying assumption is that per-generation changes in allele frequency are small. Consequently, the diffusion approximation applies when the effective population size is large and migration rates and selection coefficients are of order .
If we have samples from populations, the numbers of sampled sequences from each population are . (For diploids, is typically twice the number of individuals sampled from population 1.) Entry of the AFS records the number of diallelic polymorphic sites at which the derived allele was found in samples from population 1, from population 2, and so forth. (If ancestral alleles cannot be determined, then the “folded” AFS can be considered, in which entries correspond to the frequency of the minor allele.)
We model the evolution of , the density of derived mutations at relative frequencies in populations at time . (All run from 0 to 1.) Given an infinitely-many-sites mutational model [31] (link) and Wright-Fisher reproduction in each generation, the dynamics of for an arbitrary finite number of populations are governed by a linear diffusion equation: The first term models genetic drift, and the second term models selection and migration. Figure 1A illustrates the effects of different evolutionary forces on components of . Time is in units of , where is the time in generations and is a reference effective population size. The relative effective size of population is . The scaled migration rate is , where is the proportion of chromosomes per generation in population that are new migrants from population . (Thus migration is assumed to be conservative [32] (link)). Finally, the scaled selection coefficient is , where is the relative selective advantage or disadvantage of variants in population . Boundary conditions are no-flux except at two corners of the domain, where all population frequencies are 0 or 1; these are absorbing points corresponding to allele loss or fixation. Because the diffusion equation is linear, we can solve simultaneously for the evolution of all polymorphism by continually injecting density at low frequency in each population (at a rate proportional to the total mutation flux ), corresponding to novel mutations.
Changes in population size and migration alter the parameters in Equation 1, while population splits and mergers alter the dimensionality of . For example, if new population 3 is admixed with a proportion from population 1 and from population 2 then where denotes the Dirac delta function. To remove population 2, is integrated over : .
Given , the expected value of each entry of the AFS, , is found via a P-dimensional integral over all possible population allele frequencies of the probability of sampling derived alleles times the density of sites with those population allele frequencies. For SNP data obtained by resequencing, these probabilities are binomial, so In some cases of ascertained data [33] (link), the resulting bias can be corrected by modifying the above equation [11] (link),[34] (link).
Full text: Click here
Publication 2009
Alleles Biological Evolution Chromosomes Diffusion Diploidy Genetic Drift Genetic Polymorphism Loss of Heterozygosity Migrants Mutation Neutrophil Reproduction

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Alleles CDKN2A Gene Chromosomes Copy Number Polymorphism Diploid Cell Diploidy Exome Genome Genomic Instability Homozygote Loss of Heterozygosity Melanoma PTEN protein, human
Of the 220,231 variants on the exome array, 54,003 (covering 13,715 genes) were present in our study at sufficient frequency (minor-allele frequency >0.01%) to allow for individual-variant association testing as described in the Supplementary Appendix. In the discovery phase, we defined a suggestive novel association between a variant and the risk of coronary artery disease as one with a meta-analysis P value of 1×10−4 or lower. For variants with suggestive association, we performed association analysis in the replication studies as described in the Supplementary Appendix. We defined significant novel associations as those that were nominally significant (P<0.05) in the replication cohort and that had an overall P value of less than 7.7×10−8 in the discovery and replication cohorts combined (a Bonferroni-corrected threshold that accounted for 54,003 markers with minor-allele frequencies >0.01% being tested initially and 12 markers being tested in the replication cohort).
To test for association between variants and risk factors for coronary artery disease, we examined the relationship between low-frequency variants that were significantly associated with disease in the combined (i.e., discovery and replication) analysis and plasma lipid levels in 10,088 samples from the discovery cohort; in order to minimize any effect of ascertainment bias, we limited the analysis to persons without coronary artery disease who had lipid measurements available. We also examined the relationships between the significantly associated low-frequency variants and blood pressure in 146,562 persons from the Cohorts for Heart and Aging Research in Genomic Epidemiology Plus (CHARGE+) consortium. Tables S4 and S5 in the Supplementary Appendix list the individual studies and numbers of participants that contributed to the analyses of plasma lipid levels and blood pressure, respectively. Finally, we queried publicly available exome-array data to explore the relationship between significantly associated low-frequency variants and type 2 diabetes (data from the Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples [T2D-GENES] Consortium, Genetics of Type 2 Diabetes [GoT2D] Consortium, and the Diabetes Genetics Replication and Meta-Analysis [DIAGRAM] Consortium; accessed in November 2015 at www.type2diabetesgenetics.org/). Additional details of the risk-factor association analyses are provided in the Methods section in the Supplementary Appendix.
From the sequencing data, we used linear regression to test the association between ANGPTL4 loss-of-function alleles and plasma lipid levels in 8085 persons for whom lipid measurements were available, using models described in the Supplementary Appendix. We calculated the significance of the association between ANGPTL4 loss-of-function alleles and the risk of coronary artery disease with the use of 100,000 study-stratified permutations of case–control phenotypes.
Publication 2016
Alleles Blood Pressure Coronary Arteriosclerosis Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent DNA Replication Exome Genes Genome Heart Lipids Loss of Heterozygosity Phenotype Plasma Replicon
DNA was extracted from samples of primary brain tumor and xenografts and from patient-matched normal blood lymphocytes obtained from the Tissue Bank at the Preston Robert Tisch Brain Tumor Center at Duke University and collaborating centers, as described previously.17 (link) All analyzed brain tumors were subjected to consensus review by two neuropathologists. Table 1 lists the types of brain tumors we analyzed. The samples from glioblastomas included 138 primary tumors and 13 secondary tumors. Of the 138 primary tumors, 15 were from patients under the age of 21 years. Secondary glioblastomas were categorized as WHO grade IV on the basis of histologic criteria but had been categorized as WHO grade II or III at least 1 year earlier. Of the 151 tumors, 63 had been analyzed in our previous genomewide mutation analysis of glioblastomas. None of the lower-grade tumors were included in that analysis.16 (link)
In addition to brain tumors, we analyzed 35 lung cancers, 57 gastric cancers, 27 ovarian cancers, 96 breast cancers, 114 colorectal cancers, 95 pancreatic cancers, and 7 prostate cancers, along with 4 samples from patients with chronic myelogenous leukemia, 7 from patients with chronic lymphocytic leukemia, 7 from patients with acute lymphoblastic leukemia, and 45 from patients with acute myelogenous leukemia. All samples were obtained in accordance with the Health Insurance Portability and Accountability Act. Acquisition of tissue specimens was approved by the institutional review board at the Duke University Health System and at each of the participating institutions.
Exon 4 of the IDH1 gene was amplified with the use of a polymerase-chain-reaction (PCR) assay and sequenced in DNA from the tumor and lymphocytes from each patient, as described previously.16 (link) In all gliomas and medulloblastomas without an R132 IDH1 mutation, exon 4 of the IDH2 gene (which contains the IDH2 residue equivalent to R132 of IDH1) was sequenced and analyzed for somatic mutations. In addition, we evaluated all astrocytomas and oligodendrogliomas of WHO grade I to grade III, all secondary glioblastomas, and 96 primary glioblastomas without R132 IDH1 mutations or R172 IDH2 mutations for alterations in the remaining coding exons of IDH1 and IDH2. All coding exons of TP53 and PTEN were also sequenced in the panel of diffuse astrocytomas, oligodendrogliomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and glioblastomas. EGFR amplification and the CDKN2A-CDKN2B deletion were analyzed with the use of quantitative real-time PCR in the same tumors.18 (link) We evaluated samples of oligodendrogliomas and anaplastic oligodendrogliomas for loss of heterozygosity at 1p and 19q, as described previously.15 (link),19 (link)
Publication 2009
7-chloro-8-hydroxy-1-(3'-iodophenyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine Anaplastic Oligodendroglioma Astrocytoma Astrocytoma, Anaplastic Biological Assay BLOOD Brain Neoplasms Brain Tumor, Primary CDKN2A Gene Chronic Lymphocytic Leukemia Colorectal Carcinoma Deletion Mutation Diploid Cell EGFR protein, human Ethics Committees, Research Exons Gastric Cancer Genes Glioblastoma Glioma Grade II Astrocytomas Heterografts IDH2, human Leukemia, Myelocytic, Acute Leukemias, Chronic Granulocytic Loss of Heterozygosity Lung Cancer Lymphocyte Malignant Neoplasm of Breast Medulloblastoma Mutation Neoplasms Neuropathologist Oligodendroglioma Ovarian Cancer Pancreatic Cancer Patients Polymerase Chain Reaction Precursor Cell Lymphoblastic Leukemia Lymphoma Prostate Cancer PTEN protein, human Real-Time Polymerase Chain Reaction Tissues TP53 protein, human
The input for CONSERTING analysis is BAM files, the compressed binary version of the Sequence Alignment/Map (SAM) format21 (link), which store the alignment of WGS reads to the reference human genome. Read depth is summarized from aligned bases with quality score ≥ 15 for each base-pair position of the reference genome using the Coverage module of the program Bambino22 (link). A user-defined fixed-size window is used to obtain the mean coverage for each window. The default window size is 100bp, which was used for all analyses presented in this study. The mean read-depth per window was then normalized to a set of reference diploid chromosomal regions selected by the following criteria: no loss of heterozygosity (LOH) signal within a 1 Mb region and the coverage of the 1 Mb regions is within 1.25x median of all 1Mb non-LOH regions. Alternatively, reference diploid genomic regions may be provided by the user. The read-depth difference and the log2 ratio of the tumor and its matching normal were further normalized for GC content by linear regression.
Publication 2015
Base Pairing Chromosomes Diploidy Genome Genome, Human Loss of Heterozygosity Neoplasms Sequence Alignment

Most recents protocols related to «Loss of Heterozygosity»

Immunogenomic features were obtained from a previous pan-cancer immune landscape project performed by Thorsson et al. (18 (link)). In brief, TNB (tumor neoantigen burden) was defined as a critical target of anti-tumor immunity and calculated by the NetMHCpan algorithm (34 (link)). HRD score was used to evaluate the deficit by summation of loss of heterozygosity (LOH), large-scale transitions (LST), and genomic instability scores (GIS) (35 (link)). The relative abundance of 22 immune cell types was estimated by the CIBERSORT algorithm (36 (link)).
Full text: Click here
Publication 2023
Cells Genomic Instability Loss of Heterozygosity Malignant Neoplasms Neoplasms Response, Immune Tumor Burden
Genome-wide CRISPR–Cas9 knockout (GeCKO) v2.0 library plasmids were kindly provided by Feng Zhang [14 (link)]. The GeCKOv2.0 library A consists of 65,383 single guide RNAs (sgRNAs) that target 19,050 genes and 1864 miRNAs, causing frameshift indel mutations that lead to loss-of-function alleles. MCF7 cells were transduced with lentivirus carrying the GeCKOv2.0 library at an MOI of 0.2–0.4 for 24 h to achieve 100 × coverage of each sgRNA construct and then selected with puromycin (3 μg/mL) for 7 days. Puromycin-resistant cells were expanded for another 10 days to allow gene editing. Transwell invasion assays were performed as described, and invasive and noninvasive cells were harvested. Genomic DNA was isolated from the cells using a Blood & Cell Culture Midi kit (Qiagen). The sequences targeted by sgRNAs were amplified by the two-step PCR method, and the primer sequences for lentiCRISPR sgRNAs are listed in Additional file 1: Table S1 [14 (link), 15 (link)]. The PCR products were purified by agarose gel electrophoresis, quantified using a Qubit 3.0 Fluorometer (Invitrogen) and an ABI7900 real-time fluorescence quantitative PCR instrument (Applied Biosystems) and sequenced on a HiSeq 2500 instrument (Illumina) in single-end mode. The MAGeCK algorithm was used to analyze the FASTQ files and identify metastasis-related genes.
Full text: Click here
Publication 2023
Biological Assay BLOOD Blood Cells Blood Culture Cell Culture Techniques Cells Clustered Regularly Interspaced Short Palindromic Repeats DNA Library Electrophoresis, Agar Gel Fluorescence Frameshift Mutation Geckos Genes Genome INDEL Mutation Lentivirus Loss of Heterozygosity MCF-7 Cells MicroRNAs Neoplasm Metastasis Oligonucleotide Primers Plasmids Puromycin Real-Time Polymerase Chain Reaction RNA, Single Guide
The MCScanX installed in Tbtools (Wang et al., 2012 (link)) was used for rapid identification of intraspecies collinearity NBS-LRR genes with E-value of 10-5 in the four closely related monocotyledonous species, S. bicolor, M. sinensis, S. spontaneum and S. officinarum. The allelic loss of NBS-LRR gene in S. spontaneum and S.officinarum was calculated based on their genome annotations (http://sugarcane.zhangjisenlab.cn/sgd/html/download.html). Orthofinder-2.5.4 was used to identify homologous genes between the four species, which were conserved NBS-LRR genes, and the comparison software was Blast (E-value=10-3) (Emms and Kelly, 2015 (link)).
Full text: Click here
Publication 2023
Genes Genome Loss of Heterozygosity Saccharum
Genomic DNA from the fetus and its parents were extracted using the QIAamp® DNA Blood Mini Kit (Qiagen Inc., Hilden, Germany) according to the manufacturer’s instructions, and maternal cell contamination was ruled out using microsatellite DNA linkage analysis.
CMA was carried out using Affymetrix CytoScan 750 K array (Affymetrix Inc., Santa Clara, CA), and data was analyzed via Affymetrix Chromosome Analysis Suite Software (version 3.1.0.15) as previously described19 (link). The reporting threshold was set at gains ≥ 1 Mb, losses ≥ 500 Kb and loss of heterozygosity (LOH) ≥ 10 Mb. For fetuses with abnormal CNVs, parental testing was performed to determine its origin. CNVs were classified through OMIM, UCSC, International Standard Cytogenomic Array, Database of Genome Variants, and Decipher databases into pathogenic, likely pathogenic (LP), variants of uncertain significance (VOUS), likely benign, and benign according to the American College of Medical Genetics guidelines20 (link). Pathogenic/likely pathogenic CNVs were considered clinically significant. Parental microarray analysis was recommended to determine the origin of CNVs.
Full text: Click here
Publication 2023
BLOOD Chromosomes Fetus Genetic Linkage Analysis Genome Loss of Heterozygosity Microarray Analysis Parent Pathogenicity Short Tandem Repeat Stem Cells

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl Adult Biological Assay BRCA1 protein, human CA-125 Antigen Conferences Disease Progression Eligibility Determination Ethics Committees, Research Hypersensitivity Loss of Heterozygosity Mutation Neoplasms Patients Platinum rucaparib Tissues Woman

Top products related to «Loss of Heterozygosity»

Sourced in Germany, United States, France, United Kingdom, Netherlands, Spain, Japan, China, Italy, Canada, Switzerland, Australia, Sweden, India, Belgium, Brazil, Denmark
The QIAamp DNA Mini Kit is a laboratory equipment product designed for the purification of genomic DNA from a variety of sample types. It utilizes a silica-membrane-based technology to efficiently capture and purify DNA, which can then be used for various downstream applications.
Sourced in United States
GenomeStudio is a microarray data analysis software developed by Illumina. It provides a platform for visualization, normalization, and analysis of data generated from Illumina's microarray platforms.
Sourced in United States, United Kingdom
The CytoScan HD is a high-density microarray platform designed for cytogenetic research and clinical applications. It provides comprehensive coverage of the human genome, enabling the detection of copy number variations and chromosomal abnormalities.
Sourced in United States, United Kingdom, Canada
The CytoScan HD array is a high-resolution DNA microarray platform designed for comprehensive genomic profiling. It provides genome-wide coverage for the detection of chromosomal aberrations, including copy number variations and loss of heterozygosity.
Sourced in Germany, United States, United Kingdom, Netherlands, Japan, Spain, China, Italy, France, Australia, Canada
The QIAamp DNA FFPE Tissue Kit is a laboratory equipment designed for the purification of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples. It is used to extract high-quality genomic DNA from FFPE samples for downstream applications such as PCR, sequencing, and other molecular biology techniques.
Sourced in United States, United Kingdom
GenomeStudio software is a data analysis tool designed for Illumina microarray and sequencing platforms. It provides a unified interface to visualize, analyze, and interpret genomic data generated from Illumina instruments.
Sourced in United States, United Kingdom
The Chromosome Analysis Suite software is a tool designed for the analysis and interpretation of chromosome data. It provides a platform for visualizing, analyzing, and managing chromosome-related information generated from various laboratory techniques.
Sourced in United States
The CytoScan 750K array is a high-resolution, genome-wide microarray platform designed for cytogenetic analysis. It provides comprehensive coverage of the human genome, with approximately 750,000 markers, including both SNP and non-polymorphic probes. The CytoScan 750K array is a tool for researchers to detect and analyze chromosomal variations, copy number changes, and other genetic abnormalities.
Sourced in Germany, United States, Spain, United Kingdom, Japan, Netherlands, France, China, Canada, Italy, Australia, Switzerland, India, Brazil, Norway
The QIAamp DNA Blood Mini Kit is a laboratory equipment designed for the extraction and purification of genomic DNA from small volumes of whole blood, buffy coat, plasma, or serum samples. It utilizes a silica-based membrane technology to efficiently capture and wash DNA, while removing contaminants and inhibitors.
Sourced in United States
The Genome-Wide Human SNP Array 6.0 is a high-density genotyping microarray designed for the detection and analysis of single nucleotide polymorphisms (SNPs) across the human genome. The array contains over 900,000 SNP markers and more than 900,000 probes for the detection of copy number variations, providing a comprehensive genome-wide coverage for genetic analysis.

More about "Loss of Heterozygosity"

Loss of Heterozygosity (LOH) is a genetic phenomenon where an individual loses one of the two alleles (copies) of a gene, often resulting in increased susceptibility to diseases such as cancer.
This condition can be studied using advanced tools and technologies like PubCompare.ai, an AI-driven platform that optimizes LOH research by providing reproducible and accurate insights.
PubCompare.ai helps researchers effortlessly locate the best protocols from literature, pre-prints, and patents, boosting research efficiency and confidence.
With its cutting-edge technology, PubCompare.ai ensures seamless reproducibility and enhanced accuracy in LOH studies, enabling researchers to make more informed decisions and advance their field of study.
Researchers can also leverage other powerful tools and kits to facilitate their LOH research, such as the QIAamp DNA Mini Kit for efficient DNA extraction, GenomeStudio for data analysis, and CytoScan HD array for comprehensive chromosomal analysis.
The QIAamp DNA FFPE Tissue Kit can be used for extracting DNA from formalin-fixed, paraffin-embedded (FFPE) samples, while the Chromosome Analysis Suite software provides advanced analysis capabilities.
The CytoScan 750K array and Genome-Wide Human SNP Array 6.0 are additional tools that can be utilized to detect and analyze LOH events across the genome.
By combining these cutting-edge technologies with the insights provided by PubCompare.ai, researchers can enhance the reproducibility, accuracy, and efficiency of their LOH research, ultimately accelerating the understanding and treatment of diseases associated with this genetic phenomenon.